

# Capital Rx Drug Recall Report

MARCH 2026



Welcome to the **Capital Rx Drug Recall Report**. This report is designed to keep you up to date on the latest FDA Class 1 and Class 2 recalled drugs and market withdrawals that impact our members. It is one of the many ways we, at Capital Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

## WHO WE ARE

Capital Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. As a Certified B Corp™, Capital Rx is executing its mission through the deployment of JUDI®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. JUDI connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans. Together with our clients, we are reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. **\*\*The drug recall report is subject to change: information in this report is current as of 3/11/2026\*\***

### Privacy Statement:

*This privacy policy describes the types of information we may collect from you or that you may provide when you visit the website cap-rx.com and our practices for collecting, using, maintaining, protecting, and disclosing that information. Capital Rx, Inc. ("we," "our," or "us") is committed to ensuring that your privacy is protected. This policy applies to information we may collect through cap-rx.com, including any services offered on or through cap-rx.com such as the prescription benefit member web portal, and our mobile application accessible at the Google Play Store and iOS App Store under the name Capital Rx (collectively, our "Site").*

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
3/4/2026	Class 2	Adbry 300 Mg/2ml Injection	Leo Pharma Inc.	50222-0350-91, 50222-0350-02	A) 003E24C, EXP 04/30/2027; B) 003E24A, EXP 04/30/2027	A lack of assurance of sterility due to the presence of wool fiber.
3/4/2026	Class 2	Bio-Glo 1mg fluorescein ophthalmic strips	Wizcure Pharma Private Limited	17238-0900-11	ALL LOTS	A lack of assurance of sterility, products have not been manufactured in conformance with current good manufacturing practices.

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
3/11/2026	Class 2	Metoprolol Succinate Er 25 Mg Tb24	Teva Pharmaceuticals USA, Inc	45963-0709-11, 45963-0709-96	A) 0715J251, EXP 12/2026; 0716J251, EXP 01/2027; 0717J251, EXP 01/2027; B) 0715J252, EXP 12/2026; 0716J252, EXP 01/2027, 0717J252, EXP 01/2027	Failing to meet dissolution specifications, which may result in the tablets not dissolving properly.
3/11/2026	Class 2	Metoprolol Succinate Er 50 Mg Tb24	Teva Pharmaceuticals USA, Inc	45963-0676-11, 45963-0676-96	A) 0486G251, 0487G251, 0488G251, EXP 01/2027; B) 0486G252, 0487G253, 0488G252, EXP 01/2027	Failing to meet dissolution specifications, which may result in the tablets not dissolving properly.
3/11/2026	Class 2	Metoprolol Succinate Er 100 Mg Tb24	Teva Pharmaceuticals USA, Inc	45963-0677-11, 45963-0677-96	A) 0718J251, 0729J251, 0730J251, EXP 12/2026; B) 0718J252, 0729J252, 0730J252, EXP 12/2026	Failing to meet dissolution specifications, which may result in the tablets not dissolving properly.
3/11/2026	Class 2	Metoprolol Succinate Er 200 Mg Tb24	Teva Pharmaceuticals USA, Inc	45963-0678-11	A) 0686H251, 0687H251, 10688H251, EXP 02/2027	Failing to meet dissolution specifications, which may result in the tablets not dissolving properly.

**How do I find out more information about the recall?** View the FDA website URL for more information.

RECALL TYPE	DRUG RECALLED	FDA NOTIFICATION URL
Class 2	Adbry 300 Mg/2ml Injection	<a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218615">https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218615</a>
Class 2	Bio-Glo 1mg fluorescein ophthalmic strips	<a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218211">https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218211</a>
Class 2	Metoprolol Succinate Er 25 Mg Tb24	<a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218401">https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218401</a>
Class 2	Metoprolol Succinate Er 50 Mg Tb24	<a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218407">https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218407</a>
Class 2	Metoprolol Succinate Er 100 Mg Tb24	<a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218410">https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218410</a>
Class 2	Metoprolol Succinate Er 200 Mg Tb24	<a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218411">https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=218411</a>